Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure...

Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart
Failure and Sudden Cardiac Death

NATICK, Mass., Jan. 22 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced CE Mark approval for its COGNIS(TM)
cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM)
implantable cardioverter defibrillator (ICD). These devices represent
entirely new platforms to treat heart failure and sudden cardiac death and are
the result of a multi-year research and development effort to provide
physicians enhanced clinical options for their patients.
When choosing a high-energy device, physicians often must make trade-offs
among device size, battery longevity and features. The COGNIS CRT-D and the
TELIGEN ICD are designed to eliminate those compromises.
They are among the world's smallest and thinnest high-energy devices at
32.5 cc and 31.5 cc respectively, while less than 10 mm thick. Both devices
offer features based on significant engineering advances, including extended
battery longevity, self-correcting software and improved programming
technology. Both devices also offer SafetyCore(TM), a feature that in the
unlikely event of a system error provides lifesaving shock therapy and basic
pacing functionality.
Key features of the COGNIS CRT-D include:
-- SmartDelay(TM): quickly proposes programmable device settings, which
enables physicians to tailor individualized pacing therapy for their
patients
-- Bi-V Trigger: helps physicians manage heart failure patients with
frequent atrial arrhythmias
-- Electronic Repositioning(TM): provides physicians with six
configurations for stimulating the left side of the heart even after
implant, which may help avoid an additional surgical procedure

Key features of the TELIGEN ICD include:
-- Thinnest device available in the world, designed with patient comfort
in mind
-- Reverse Mode Switch(TM): designed to eliminate unnecessary ventricular
pacing
-- Quick Convert(TM): provides the ability for patients to receive pacing
therapy for ventricular tachycardias

"Our CRM team is refocused on delivering therapy systems that meet
clinician needs for safety, reliability and better patient outcomes," said Jim
Tobin, President and Chief Executive Officer of Boston Scientific. "We have
re-engineered the way we design, build, test and report on our technology.
The COGNIS CRT-D and the TELIGEN ICD are testaments to the revitalization of
our CRM business and are just two of the many new products we plan to launch
in 2008."
The first COGNIS and TELIGEN implants are scheduled to take place early
next month. The Company plans to build to a full launch in Europe and other
international markets in the second quarter.
The COGNIS CRT-D and the TELIGEN ICD are pending approval by the U.S. Food
and Drug Administration and are not available for sale in the United States.
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These forward-
looking statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding our product performance, regulatory
approval of our products, new product launches, competitive offerings, our
growth strategy, and our market position. If our underlying assumptions turn
out to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.
Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A- Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any forward-
looking statements to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be based, or that
may affect the likelihood that actual results will differ from those contained
in the forward-looking statements. This cautionary statement is applicable to
all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Dan Brennan
508-650-8538 (office)
617-459-2703 (mobile)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

Paul Donovan, Media Relations, +1-508-650-8541, Mobile, +1-508-667-5165, or
Dan Brennan, Investor Relations, +1-508-650-8538, Mobile, +1-617-459-2703,
both of Boston Scientific Corporation